Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides caloric support, replenishes glycogen stores, and prevents ketosis by supplying glucose for cellular energy metabolism. Sodium chloride maintains osmotic balance and replaces extracellular fluid and electrolytes.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Fluid and electrolyte replacement,Treatment of dehydration,Intravenous infusion to provide calories and maintain blood glucose levels,Diluent for compatible medications
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion; rate and volume determined by patient fluid and electrolyte needs, typically 1-2 L/day in adults.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Exogenous dextrose has a plasma half-life of approximately 15–20 minutes under normal metabolic conditions; in hyperglycemia or insulin resistance, half-life is prolonged.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose is metabolized via glycolysis and the Krebs cycle to produce carbon dioxide, water, and energy. Sodium and chloride ions are excreted primarily by the kidneys.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Exogenous dextrose is fully metabolized to carbon dioxide and water; no significant renal or biliary excretion of intact dextrose. Sodium and chloride are primarily excreted renally (greater than 90% of filtered load reabsorbed; excess excreted in urine).
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Dextrose: negligible (<5%) protein binding. Sodium and chloride: not protein bound.
Low protein binding; 0–11% bound, primarily to albumin.
Dextrose: distributes into total body water, approximately 0.55–0.6 L/kg (in adults); sodium distributes primarily in extracellular fluid (0.2 L/kg).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100% bioavailable. Not administered via oral, intramuscular, or subcutaneous routes for caloric or fluid replacement (oral dextrose has high first-pass metabolism).
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
No specific dose adjustment required; monitor fluid and electrolyte balance in renal impairment. In severe renal failure (GFR <15 m L/min), reduce volume to avoid fluid overload.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific dose adjustment required; monitor glucose and electrolytes in severe hepatic impairment due to risk of glucose intolerance.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Intravenous infusion; dose based on weight and clinical condition. Typical maintenance: 4-8 mg/kg/min dextrose for neonates, 100-150 m L/kg/day for infants, adjusting for fluid and electrolyte needs.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Use with caution; reduced renal function may require lower infusion rates and smaller volumes to avoid fluid overload. Monitor serum glucose and electrolytes closely.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
No FDA boxed warning.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of hyperglycemia, especially in patients with diabetes mellitus,Monitor serum electrolytes and fluid balance to avoid hypernatremia or fluid overload,Contraindicated in patients with hypertonic dehydration, hypernatremia, or hyperglycemia with ketosis,Use with caution in patients with congestive heart failure, renal failure, or liver cirrhosis,Large volumes may cause electrolyte disturbances or osmotic diuresis
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypertonic dehydration,Hypernatremia,Severe hyperglycemia with ketosis,Known hypersensitivity to dextrose or sodium chloride,Intracranial or intraspinal hemorrhage (if administered via cerebrospinal fluid routes)
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No specific food interactions. However, concurrent administration of high-sugar or high-sodium foods may exacerbate hyperglycemia or hypernatremia. Monitor dietary intake of carbohydrates and sodium.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Dextrose 5% in 0.2% sodium chloride is a maintenance fluid; no teratogenic risk identified at standard doses. Maternal hyperglycemia from excessive dextrose may cause fetal hyperinsulinism and neonatal hypoglycemia, particularly in third trimester. Hypoosmolar states from improper administration could impair placental perfusion.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Dextrose and sodium chloride are normal components of breast milk; no adverse effects expected at standard infusion rates. M/P ratio not applicable as endogenous substances.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Dose adjustments not typically required. Monitor glucose closely and reduce infusion rate or switch to lower dextrose concentration if hyperglycemia develops. Increased plasma volume in pregnancy may necessitate higher total fluid volumes to maintain euvolemia, but sodium content should be considered to avoid edema.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Monitor serum glucose and electrolytes during prolonged infusion. Administer via large peripheral or central vein to prevent phlebitis. Use with caution in patients with renal impairment, heart failure, or hyperglycemia. Do not administer if solution is discolored or contains particulates. Incompatible with blood products via same line.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Inform your doctor if you have diabetes, heart failure, or kidney problems.,Report any signs of infusion site reactions like pain, redness, or swelling.,This solution contains sugar and salt; do not consume additional salt or sugar without medical advice.,You may need frequent blood tests to monitor your sugar and electrolyte levels.,Do not use this solution at home unless specifically instructed and trained.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides caloric support, replenishes glycogen stores, and prevents ketosis by supplying glucose for cellular energy metabolism. Sodium chloride maintains osmotic balance and replaces extracellular fluid and electrolytes.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by patient fluid and electrolyte needs, typically 1-2 L/day in adults.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose 5% in 0.2% sodium chloride is a maintenance fluid; no teratogenic risk identified at standard doses. Maternal hyperglycemia from excessive dextrose may cause fetal hyperin. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.